Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations

Area of Science:

• Nephrology
• Health Services Research
• Clinical Chemistry

Background:

• National payment policies aim for hemoglobin levels of 11 to 12.5 g/dL for end-stage renal disease (ESRD) patients.
• Clinical complications and provider practices can cause significant hemoglobin level variability over time.

Purpose of the Study:

• To determine the frequency of stable hemoglobin levels within, below, and above the target range.
• To assess hemoglobin fluctuation patterns and their association with clinical outcomes over a 6-month period.

Main Methods:

• Analysis of Medicare data for 152,846 hemodialysis patients surviving the first 6 months of 2003.
• Categorization of patients into six groups based on hemoglobin fluctuation patterns (stable low, stable target, stable high, low-amplitude low, low-amplitude high, high-amplitude).

Main Results:

• Only 10.3% of patients maintained stable hemoglobin levels; 6.5% stayed within the target range.
• High-amplitude fluctuation was the most common pattern (39.5%), with levels crossing the target range.
• The consistently low hemoglobin group exhibited the highest hospitalization rates and comorbidity burden.

Conclusions:

• Hemoglobin levels fluctuate significantly in most hemodialysis patients, with nearly 90% showing some degree of flux.
• Hemoglobin variability is strongly associated with clinical complications and potentially influenced by provider practices.
• Current payment policies may not adequately address the challenges of maintaining stable hemoglobin levels in ESRD patients.